title: Dalbavancin (Biosearch Italia/Versicor).
abstract: Biosearch Italia and Versicor are developing dalbavancin, a novel semisynthetic derivative of the natural glycopeptide A-40926 for the potential treatment of Gram-positive infections. In May 2001, the compound entered phase II trials in the US [409929], [409932]. As of Janaury 2002, phase II trials in skin infections and bacteremia were ongoing [436430]. Both dalbavancin and MDL-63246 are dimethylaminopropyl amide derivatives of A-40926; dalbavancin differs from MDL-63246 in its acylamino sugar, which consists of glucuronic acid in dalbavancin and glucosamine in MDL-63246 [216093], [298527]. The development of MDL-63246 has been discontinued [298527]. In January 1999, Versicor gained North American market rights to BI-397 [311500]. In January 2002, UBS Warburg predicted filing of an NDA in the second half of 2003 for dalbavancin, for treatment of complicated skin and soft tissue infections [439472]. In December 2001, Lehman Brothers predicted a late 2005 launch for dalbavancin, with sales of US $7.7 million in 2005, US $65.8 million in 2006, and peak sales of US $225 million in 2008 [439469].
authors.affiliation: Institute for Medical Microbiology Virology, Universitätsklinikum Düsseldorf, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Steiert
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Schmitz
mesh_terms: D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001682:Biological Availability; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003872:Dermatitis / Q000188:drug therapy*; D004345:Drug Industry; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006020:Glycopeptides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008826:Microbial Sensitivity Tests; D013329:Structure-Activity Relationship; D017334:Teicoplanin / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D015507:Drugs, Investigational; D006020:Glycopeptides; D017334:Teicoplanin; C469289:dalbavancin